Nippon Chemiphar Co., Ltd. (4539) AI Stock Analysis

• Market Cap: ¥5.40B
• Dividend Yield: 3.34%
• Average Volume (3M): 1.79K
• Price to Earnings (P/E): 18.4
• Beta (1Y): 0.23
• Revenue Growth: 5.93%
• EPS Growth: N/A
• Country: JP
• Employees: 887
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 71.90
• Shares Outstanding: 4,261,420
• 10 Day Avg. Volume: 2,000
• 30 Day Avg. Volume: 1,786
• PEG Ratio: 0.08
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,628.00
• Price Target Upside: 8.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: ¥1,657.00 ▲(10.69%Upside)

Nippon Chemiphar's overall stock score is influenced most significantly by its stable financial performance, despite cash flow challenges. Technical analysis points to a positive price trend, with the stock trading above key moving averages. Valuation is reasonable with an attractive dividend yield, making it appealing for income-focused investors. Limited data from earnings calls and corporate events did not impact the score.

Nippon Chemiphar Co., Ltd. Business Overview & Revenue Model

Company Description

Nippon Chemiphar Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company focuses on both prescription and over-the-counter drugs, with a strong emphasis on generic medications. Through its innovative R&D efforts, Nippon Chemiphar aims to address various medical needs and improve patient health outcomes. Its product portfolio includes treatments for cardiovascular, metabolic, and infectious diseases, among others.

How the Company Makes Money

Nippon Chemiphar Co., Ltd. generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include the production and distribution of generic drugs, which offer cost-effective alternatives to branded medications. Additionally, Nippon Chemiphar invests in research and development to create proprietary drugs, which can command higher prices and profit margins. The company also engages in strategic partnerships and collaborations with other pharmaceutical firms to expand its market reach and leverage shared expertise. These partnerships can include licensing agreements, co-development projects, and distribution arrangements that contribute to the company's earnings. Overall, Nippon Chemiphar's diversified product portfolio and strategic alliances are significant factors in its revenue generation.

Nippon Chemiphar Co., Ltd. Financial Statement Overview

Summary

Nippon Chemiphar displays a mixed financial performance. The income statement shows signs of recovery with improved margins, although revenue growth has been inconsistent. The balance sheet remains stable with manageable leverage and a strong equity base. Cash flow issues persist, with negative free cash flow indicating ongoing liquidity challenges. Overall, while the company shows potential, it faces risks from cash flow constraints and fluctuating profitability.

Income Statement

Nippon Chemiphar has shown inconsistent revenue growth with a 5.9% increase in the latest year after a decline in the previous year. The gross profit margin stands at 26.8%, which is moderate. However, the net profit margin has improved to 0.9% from a loss last year, indicating a positive turnaround in profitability. The EBITDA margin improved to 5.6%, showing healthier operational efficiency, but the EBIT margin remains low at 1.9%.

Balance Sheet

The company's debt-to-equity ratio of 0.94 indicates a balanced leverage profile. The return on equity is 1.5%, reflecting modest profitability relative to shareholder equity. The equity ratio of 38.5% suggests a solid capital structure, providing stability despite the modest ROE.

Cash Flow

The company faced a free cash flow deficit, although the negative growth rate has slightly improved from the previous year. The operating cash flow to net income ratio is negative due to operating cash flow being negative, indicating potential liquidity challenges. The free cash flow to net income ratio is also negative, signaling difficulties in converting profits into cash.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	32.57B	30.75B	31.56B	32.51B	31.54B
Gross Profit	8.75B	7.74B	8.19B	9.07B	11.44B
EBITDA	1.83B	1.40B	1.26B	2.41B	1.96B
Net Income	294.00M	-180.00M	339.00M	700.00M	495.00M
Balance Sheet
Total Assets	49.85B	49.55B	48.57B	49.45B	47.12B
Cash, Cash Equivalents and Short-Term Investments	7.02B	9.20B	10.53B	11.64B	10.58B
Total Debt	18.06B	16.98B	15.23B	14.79B	15.37B
Total Liabilities	30.68B	31.09B	30.04B	30.95B	29.11B
Stockholders Equity	19.17B	18.46B	18.53B	18.50B	18.01B
Cash Flow
Free Cash Flow	-1.86B	-2.34B	-1.93B	1.07B	-85.00M
Operating Cash Flow	-265.00M	296.00M	-916.00M	1.80B	1.50B
Investing Cash Flow	-1.66B	-3.14B	-394.00M	35.00M	-1.02B
Financing Cash Flow	-305.00M	1.45B	144.00M	-793.00M	29.00M

Nippon Chemiphar Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1497.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4539, the sentiment is Positive. The current price of 1497 is above the 20-day moving average (MA) of 1495.50, above the 50-day MA of 1486.70, and above the 200-day MA of 1470.88, indicating a bullish trend. The MACD of 4.27 indicates Positive momentum. The RSI at 51.77 is Neutral, neither overbought nor oversold. The STOCH value of 49.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4539.

Nippon Chemiphar Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	78 Outperform	¥8.92B	16.27		2.52%	2.90%	-21.60%
4539	70 Outperform	¥5.40B	18.41		3.34%	5.93%	―
4569	70 Outperform	¥79.06B	9.50		0.67%	8.83%	70.61%
4538	65 Neutral	¥18.63B	6.46		3.95%	9.31%	-340.82%
4582	51 Neutral	¥8.38B	―		―	-56.12%	-73.82%
4512	50 Neutral	¥10.03B	155.65		1.04%	0.66%	-40.86%
Sector *	46 Neutral	C$197.02M	-3.33	-23.14%	2.65%	20.75%	-0.36%